​

Akari Therapeutics (AKTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

AKTX Stock Forecast

Akari Therapeutics (AKTX) stock forecast, based on 7 Wall Street analysts, predicts a 12-month average price target of $30.00, with a high of $30.00 and a low of $30.00. This represents a 2464.10% increase from the last price of $1.17.

- $6 $12 $18 $24 $30 High: $30 Avg: $30 Low: $30 Last Closed Price: $1.17

AKTX Stock Rating

Akari Therapeutics stock's rating consensus is Buy, based on 7 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (85.71%), 1 Hold (14.29%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 7 0 1 6 Strong Sell Sell Hold Buy Strong Buy

AKTX Price Target Upside V Benchmarks

TypeNameUpside
StockAkari Therapeutics2464.10%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.17$1.17$1.17
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25-1---1
Nov, 242-1--3
Oct, 24211--4
Sep, 24211--4
Aug, 24212--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2022H.C. Wainwright$30.00$10.77178.55%2464.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26
Dec 23Dec 24Dec 25Dec 26
Reported----
Avg Forecast$-4.00$-3.40$-3.60-
High Forecast$-4.00$-3.40$-3.60-
Low Forecast$-4.00$-3.40$-3.60-
Surprise %----

Revenue Forecast

$0 $8M $16M $24M $32M $40M Dec 23 Dec 24 Dec 25 Dec 26
Dec 23Dec 24Dec 25Dec 26
Reported----
Avg Forecast-$36.60M$3.54M$9.58M
High Forecast-$36.60M$3.54M$9.58M
Low Forecast-$36.60M$3.54M$9.58M
Surprise %----

Net Income Forecast

Dec 23 Dec 24 Dec 25 Dec 26
Dec 23Dec 24Dec 25Dec 26
Reported$-10.01M$-19.79M--
Avg Forecast$-19.58M$-16.64M$-17.62M-
High Forecast$-19.58M$-16.64M$-17.62M-
Low Forecast$-19.58M$-16.64M$-17.62M-
Surprise %-48.88%18.93%--

AKTX Forecast FAQ

Is Akari Therapeutics stock a buy?

Akari Therapeutics stock has a consensus rating of Buy, based on 7 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Akari Therapeutics is a favorable investment for most analysts.

What is Akari Therapeutics's price target?

Akari Therapeutics's price target, set by 7 Wall Street analysts, averages $30 over the next 12 months. The price target range spans from $30 at the low end to $30 at the high end, suggesting a potential 2464.10% change from the previous closing price of $1.17.

How does Akari Therapeutics stock forecast compare to its benchmarks?

Akari Therapeutics's stock forecast shows a 2464.10% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Akari Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 66.67% Strong Buy, 0% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • October 2024: 50.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.

What is Akari Therapeutics’s EPS forecast?

Akari Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-3.6, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are.

What is Akari Therapeutics’s revenue forecast?

Akari Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.54M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for.

What is Akari Therapeutics’s net income forecast?

Akari Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-17.62M, representing a -10.97% decrease from the reported $-19.791M in 2024. Projections indicate .